Drugs / Eight Treg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06777719 | Mar 2025 → May 2027 expected | — | Nantes University Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eight Treg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06777719 ↗ |
| Modality | Cell therapy | “an autologous cell therapy product containing CD8+ regulatory T lymphocytes (Tregs) expanded ex vivo during 21 days of cell culture.” NCT06777719 ↗ |
| Route | Intravenous | “given to patients with a peripheral IV infusion the day before the graft” NCT06777719 ↗ |